Shijiazhuang Pharma Group

It joins a growing crop of so-called neuroplastogen developers, including Delix Therapeutics, which we reported last month, could be in line to receive fresh investment from various parties, including the large pharmaceutical firm Johnson & Johnson.

Other drug developers working in this segment include Hong Kong-based CSPC Pharmaceutical Group, which is also launching a phase one study of its non-hallucinogenic candidate.

Sticking with companies, Eli Lilly's acquisition of psychedelic drug developer Atai Beckley has officially closed.

Eli Lilly, the largest pharmaceutical company in the world by many measures, is shelling out $2.8 billion in cash to acquire the company with up to an extra billion dollars in milestones thereafter.